NR4A1 and breast carcinoma: Homologous recombination deficiency (HRD) scores and hormone receptor subtype are predictive of immunogenicity in BRCA1/2 breast cancers and may aid in designing optimal immune therapeutic strategies, as suggested by Kraya et al. [126].